Handbook of Therapeutic Antibodies - gebunden oder broschiert

EAN (ISBN-13): 9783527329373
ISBN (ISBN-10): 3527329374
Gebundene Ausgabe
Erscheinungsjahr: 2014
Herausgeber: Wiley-VCH

Buch in der Datenbank seit 2014-09-29T10:54:04+02:00 (Berlin)
Detailseite zuletzt geändert am 2023-11-08T13:14:06+01:00 (Berlin)
ISBN/EAN: 9783527329373

ISBN - alternative Schreibweisen:
3-527-32937-4, 978-3-527-32937-3
Alternative Schreibweisen und verwandte Suchbegriffe:
Autor des Buches: stefan, reiche, reichert, reich, jan, dübel, wiley vch, reicher, dube
Titel des Buches: the handbook, dubel, anti anti, using antibodies, the hand

---

Daten vom Verlag:

Autor/in: Stefan Dübel; Janice M. Reichert
Titel: Handbook of Therapeutic Antibodies
Verlag: Wiley-Blackwell; Wiley-VCH
2544 Seiten
Erscheinungsjahr: 2014-09-10
Gedruckt / Hergestellt in Singapur.
Gewicht: 6,386 kg
Sprache: Englisch
789,00 € (DE)
Not available (reason unspecified)
170mm x 244mm x 150mm

SA; BB; Hardcover, Softcover / Biologie/Mikrobiologie; Biologie, Biowissenschaften; Verstehen; Biowissenschaften, Biologie; Antikörper; Biotechnologie; Biotechnologie i. d. Biowissenschaften; Biotechnology; Biowissenschaften; Chemie; Chemistry; Life Sciences; Medical Science; Medizin; Pharmaceutical & Medicinal Chemistry; Pharmacology & Pharmaceutical Medicine; Pharmakologie u. Pharmazeutische Medizin; Pharmazeutische u. Medizinische Chemie; Pharmazeutische u. Medizinische Chemie; Biotechnologie i. d. Biowissenschaften; Pharmakologie u. Pharmazeutische Medizin; Biotechnologie

VOLUME I: DEFINING THE RIGHT ANTIBODY COMPOSITION Therapeutic Antibodies - From Past to Future (Stefan Dübel) PART 1: SELECTING AND SHAPING THE ANTIBODY MOLECULE Selection Strategies I: Monoclonal Antibodies (Gerhard Moldenhauer) Selection Strategies II: Antibody Phage Display (Michael Hust, Andre Frenzel, Florian Tomszak, Jonas Köller) Transgenic Animals Derived by DNA Microinjection (Marianne Brüggemann, Michael J. Osborn, Biao Moa, Suzanne Avis, Ignacio Anegon, Roland Bülow) Molecular Engineering I: Humanisation Strategies (Jose Saldanha) Antibody Affinity (Andre Frenzel, Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends, Larry Green) Molecular Engineering III: Fc (Thomas Valerius, Matthias Peipp, Stefanie Derer, Stefan Lohse, Christian Kellner) Glycosylation of Antibody Molecules (Roy Jefferis) Bioinformatics Tools for Analysis of Antibodies (Andrew C. R. Martin, James Allen) How to use IMGT for Therapeutic Antibody Engineering (Marie-Paul Lefranc) PART 2: MODIFIED ANTIBODIES Bispecific Antibodies (Roland E. Kontermann, Dafne Müller) Single Domain Antibodies: An Overview (Carrie Enever, Edward Coulstock, Malgorzata Pupecka-Swider, B. Hamilton) Antibody-Drug Conjugates (ADCs): New Frontier in Cancer Therapeutics (Ravi Chari, Rajeeva Singh, John M. Lambert) Antibody Targeted Drugs: From Chemical Immunoconjugates to Recombinant Fusion Proteins (Jürgen Krauss, Athanasios Mavratzas, Michaela A. E. Arndt, Stefan Kiesgen) PART 3: EMERGING TECHNOLOGIES Emerging Technologies for Antibody Selection (Mike Taussig, Mingyue He) Anti-idiotypic Antibodies (Alejandro Lopez-Requena, Oscar Roberto Burrone, Rolando Perez) Non-antibody Scaffolds as Alternative Therapeutic Agents (Arne Skerra, Markus Fiedler) Antibody Directed Enzyme Prodrug Therapy (ADEPT) (Surinder K. Sharma, Kerry A. Chester, Kenneth D. Bagshawe) Engineered Antibody Domains as Candidate Therapeutics (Weizao Chen, Ponraj Prabakaran, Dimiter S. Dimitrov) Chimeric Antigen Receptors - "CARs" (Thomas Schirrmann, Ulf Petrausch) Emerging Alternative Production Systems (Thomas Jostock, Benjamin Sommer, Holger Laux, Andre Frenzel) VOLUME II: CLINICAL DEVELOPMENT OF ANTIBODIES PART 4: THE WAY INTO THE CLINIC Process Development and Manufacturing of Therapeutic Antibodies (Hitto Kaufmann, Alexander Jacobi, Barbara Enenkel, Patrick Garidel, Christian Eckermann, Mathias Knappenberger, Ingo Presser) The Immunogenicity of Therapeutic Antibodies (Melody Sauerborn) Biosimilar Monoclonal Antibodies (Susanne D. Pippig, Carsten Brockmeyer, Robert E. Zoubek) Patent Issues Relating to Therapeutic Antibodies (Michael Braunagel, Barbara Rigby, Deborah Owen) PART 5: THERAPEUTIC ANTIBODY PIPELINE Monoclonal Antibodies in Phase III Clinical Trials (Peter Markus Deckert, Ulf Petrausch) Antibodies in Early Phase Clinical Studies: Cancer Therapy (Anthony Olszanski, Matthew Zibelman, Hossein Borghaei) Targeting Angiogenesis by Therapeutic Antibodies (Thomas Effert, Onat Kadioglu, Ean Jeong Seo) Antibodies in Phase 3: Immunological Disorders (Penelope Ward, Mark Bodmer) Monoclonal Antibodies in Phase 1 and 2 Studies for Immunological Disorders (Frank Brennan) MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders (Frank Brennan) T Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) B Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) Inhibitors of Leukocyte Adhesion and Migration in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) Toll-Like Receptor Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) IgE Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) Complement Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) mAbs Targeting Apoptosis, Angiogenesis Inhibitors and other mAbs in Phase 1 and 2 Clinical Studies for Immunological Disorders (Frank Brennan) Antibodies in Clinical Study: Infectious Diseases (Guillaume Descoubeaux) Immunotherapeutics for Neurological Disorders (Anne Messer, Kevin Manley, Cynthia A. Lemere) PART 6: GAINING MARKETING APPROVAL Regulatory Considerations in the Development of Monoclonal Antibodies for Diagnosis and Therapy (Marjorie A. Shapiro, Patrick G. Swann, Stacey Ricci) Regulatory Review: Clinical to Market Transition (Gabriele Dallmann) Monoclonal antibody nomenclature for clinical studies (USA) (Stephanie Shubat) VOLUME III: APPROVED THERAPEUTIC ANTIBODIES PART 7: APPROVED THERAPEUTIC ANTIBODIES Oligoclonal and Polyclonal Antibody Preparations (Mark C. Glassy, Rishab K. Gupta) Adalimumab (Humira) (Janice Reichert) Alemtuzumab (Lemtrada, MabCampath) (Janice Reichert, Thomas Elter, Michael Hallek) Basiliximab and Daclizumab (Nasimul Ahsan, Burcin Taner, Nadim Mahmud) Belimumab (Benlysta) (David P. D´Cruz, Pamela M.K. Lutalo, Natasha Jordan, Thi-Sau Migone) Brentuximab vedotin (Adcetris) (Neils van de Donk) Canakinumab (ILARIS) (Hermann Gram) Catumaxomab (Removab) - Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination (Horst Lindhofer, M. Stanglmaier, R. Buhmann, M. Jäger, D. Klunker, P. Ruf, J. Hess) Cetuximab (Erbitux) (Sonja Wilke, Michael Hust) Denosumab (Prolia) (Torsten Meyer) Efalizumab (Raptiva) (Karlheinz Schmitt-Rau) Calicheamycin Conjugates: Gemtuzumab Ozogamicin (Mylotarg), Inotuzumab Ozogamicin (Martin Gramatzki, Matthias Peipp) Golimumab (Simponi) (Janice Reichert, Sohini Mazumdar) Yttrium-90 Ibritumomab Tiuxetan (Zevalin) (Karin Hohloch, Björn Chapuy, Lorenz Trümper) Infliximab (Remicade) (Christian Antoni) Ipilimumab (Yervoy) (Javier Puente, Teresa Alonso Gordoa, Eduardo Diaz-Rubio) Muromonab-CD3 (Orthoclone OKT3) (Janice Reichert, Harald Becker) Nimotuzumab: A Humanized Anti-EGFR Antibody (Tania Crombet) Obinutuzumab (Christian Klein, Marina Bacac, Pablo Umana, Michael Wenger) VOLUME IV: APPROVED THERAPEUTIC ANTIBODIES AND IN VIVO DIAGNOSTICS Ofatumumab: A Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent Cytotoxicity (Ronald P. Taylor, Margaret A. Lindorfer, Joost Bakker, Paul Parren) Omalizumab (Xolair) - Anti-Immunoglobulin E Treatment in Allergic Diseases (Klaus Kroegel, Martin Foerster) Palivizumab (Louis Bont) Panitumumab (Vectibix) - A Treatment for Metastatic Colorectal Cancer (Jonas Kügler) Pertuzumab (Perjeta) (Jose Angel Garcia-Saenz, Fernando Moreno Anton, Coralia Bueno Muino) Ranibizumab (Lucentis): A New Anti-angiogenic Treatment in Ophthalmology (Nicolas Leveziel, Marc Ohresser, Gilles Paintaud) Raxibacumab - Human Monoclonal Antibody Against Anthrax Toxin (Sally Bolmer, Thi-Sau Migone) Rituximab (Rituxan) (Stefan Dübel, Axel Boehnke, Michael Wenger) Tocilizumab (Actemra) (Graeme Jones) Trastuzumab (Herceptin) and Ado-Trastuzumab Emtansine (T-DM1) (M. H. Ruhe Chowdhury, Paul Ellis) Ustekinumab (Stelara) (Stefan Dübel, Oya Cingoz, Janice Reichert) Abciximab, Bevacizumab, Certolizumab pegol, Eculizumab, Natalizumab (Janice Reichert) Itolizumab (Alzumab), Mogamulizumab (Poteligeo) and Tositumomab (Bexxar) (Stefan Dübel) PART 8: IN VIVO DIAGNOSTICS Radiolabeled Antibodies for Diagnostic Imaging (Christopher J. Palestro) Appendix Index